Alan Moss | Profiles RNS

Alan C. Moss, MD

Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

Gastroenterology

MBChB, Royal College of Surgeons in Ireland
PhD, University College Dublin

Websites

	Boston Medical Center Provider Profile
	LinkedIn

ORCID : 0000-0003-0179-5477

Alan Moss, MD, FACG, AGAF, FEBG, FRCPI is a clinician-scientist with an interest in Crohn's disease and Ulcerative Colitis (Inflammatory Bowel Disease, IBD). His clinical expertise is in management of IBD, and he is Director of the Crohn's & Colitis Program at Boston Medical Center. His research interests include microbial therapeutics, mucosal immunology and clinical outcomes. He has held grant funding from NIDDK, AGA, Helmsley Charitable Trust, and the Crohn's & Colitis Foundation. He has published over 120 research papers (h-index 28), including many cited in national and international practice guidelines. Dr Moss has held positions as Deputy-Editor of Crohn's & Colitis 360, and as Associate Editor for Journal of Crohn’s & Colitis (ECCO), Frontline Gastroenterology (BMJ) and the World Journal of Gastroenterology. He has served on the Nominating Committee of the IBD section of AGA, and the Professional Education and National Scientific Advisory Committee for the Crohn's & Colitis Foundation. He is a reviewer for national and international research bodies, including the NIDDK and European Research Council.

BMC Research

VE202-002: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF VE202 IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS
07/19/2023 - 07/19/2024 (PI)
Vedanta Biosciences, Inc.

ABX464-105: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
07/19/2023 - 07/19/2024 (PI)
Abivax

Staging Crohn’s Disease using Mucosal Exosomes
12/01/2019 - 12/31/2022 (PI)
The Leona M. and Harry B. Helmsley Charitable Trust

Litwin IBD Pioneers Award (LTW) Intestinal Microbial Therapy to Prevent Endoscopic Crohn's…
08/01/2019 - 08/31/2022 (PI)
Crohn's & Colitis Foundation of America / CCFA

IBD-CME CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry
07/01/2021 - 06/30/2022 (PI)
CorEvitas

Fecal Exosomes as Biomarkers of Inflammatory Pathways in Inflammatory Bowel…
10/25/2019 - 06/30/2021 (PI)
Pfizer, Inc

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Apr; 19(4):431-438. PMID: 37051666

Tandon K, Moss AC. Let thy food be thy medicine. Frontline Gastroenterol. 2023; 14(1):3. PMID: 36561786; PMCID: PMC9763640; DOI: 10.1136/flgastro-2022-102235;

Moss AC. Approach to Treatment Failure in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2022 Jun; 18(6):360-363. PMID: 36398141; PMCID: PMC9666824

Goldowsky A, Singh R, Charabaty A, Moss AC. P033 Moving the Needle on Speaker Diversity at AIBD. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S8.View Related Profiles.

Moss, Alan
Goldowsky, Alexander

PMID: 37461952

Goldowsky A, Singh R, Charabaty A, Moss AC. P033 Moving the Needle on Speaker Diversity at AIBD. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S8.View Related Profiles.

Moss, Alan
Goldowsky, Alexander

PMID: 35006161

Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 10 18; 27(10):1552-1563. PMID: 34279600; PMCID: PMC8861367; DOI: 10.1093/ibd/izab155;

Ayyar KK, Moss AC. Exosomes in Intestinal Inflammation. Front Pharmacol. 2021; 12:658505. PMID: 34177577; PMCID: PMC8220320; DOI: 10.3389/fphar.2021.658505;

Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis. 2021 01 19; 27(2):207-214. PMID: 32170946; DOI: 10.1093/ibd/izaa048;

Harshe RP, Xie A, Vuerich M, Frank LA, Gromova B, Zhang H, Robles RJ, Mukherjee S, Csizmadia E, Kokkotou E, Cheifetz AS, Moss AC, Kota SK, Robson SC, Longhi MS. Endogenous antisense RNA curbs CD39 expression in Crohn's disease. Nat Commun. 2020 11 18; 11(1):5894. PMID: 33208731; PMCID: PMC7676266; DOI: 10.1038/s41467-020-19692-y;

Donet JA, Charabaty A, Moss AC. Management of Asymptomatic Terminal Ileitis. Crohns Colitis 360. 2020 Oct; 2(4):otaa065. PMID: 36777745; PMCID: PMC9802103; DOI: 10.1093/crocol/otaa065;

Showing 10 of 159 results. Show More

Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 12; 49(4):689-704. PMID: 33121689

Bhat S, Farraye FA, Moss AC. Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic. Am J Gastroenterol. 2020 09; 115(9):1532-1533.View Related Profiles.

Moss, Alan
Farraye, Francis

PMID: 32694291; PMCID: PMC7396223; DOI: 10.14309/ajg.0000000000000787;

Cohen BL, Gallinger ZR, Ha C, Holubar SD, Hou JK, Kinnucan J, Mahadevan U, Moss AC, Raffals LE, Regueiro M, Szigethy E, Wolf D, Dubinsky MC, Patel A, Shah BJ, Ehrlich OG, Hanauer SB. Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305. PMID: 32820340

Robles RJ, Mukherjee S, Vuerich M, Xie A, Harshe R, Cowan PJ, Csizmadia E, Wu Y, Moss AC, Chen R, Robson SC, Longhi MS. Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease. J Crohns Colitis. 2020 Jul 09; 14(6):818-830. PMID: 31693091; PMCID: PMC7457187; DOI: 10.1093/ecco-jcc/jjz182;

Segal JP, Moss AC. Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterol. 2021; 12(4):316-321. PMID: 34249317; PMCID: PMC8231424; DOI: 10.1136/flgastro-2020-101531;

Bai A, Moss A, Rothweiler S, Longhi MS, Wu Y, Junger WG, Robson SC. Author Correction: NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2020 06 10; 11(1):3036. PMID: 32522986; PMCID: PMC7287065; DOI: 10.1038/s41467-020-16314-5;

Bhat S, Farraye FA, Moss A. Roles of Clinical Pharmacists in Caring for Patients With Inflammatory Bowel Disease During COVID-19. Gastroenterology. 2021 04; 160(5):1880.View Related Profiles.

Moss, Alan
Farraye, Francis

PMID: 32425232; PMCID: PMC7233231; DOI: 10.1053/j.gastro.2020.05.044;

Gubatan J, Mehigan GA, Villegas F, Mitsuhashi S, Longhi MS, Malvar G, Csizmadia E, Robson S, Moss AC. Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells. Inflamm Bowel Dis. 2020 05 12; 26(6):885-897. PMID: 31955203; PMCID: PMC7216768; DOI: 10.1093/ibd/izz330;

Chen J, Haller CA, Jernigan FE, Koerner SK, Wong DJ, Wang Y, Cheong JE, Kosaraju R, Kwan J, Park DD, Thomas B, Bhasin S, De La Rosa RC, Premji AM, Liu L, Park E, Moss AC, Emili A, Bhasin M, Sun L, Chaikof EL. Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists. Sci Adv. 2020 01; 6(3):eaay8230.View Related Profiles.

Moss, Alan
Emili, Andrew

PMID: 31998845; PMCID: PMC6962035; DOI: 10.1126/sciadv.aay8230;

Lee MSL, Ramakrishna B, Moss AC, Gold HS, Branch-Elliman W. Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia. Transpl Infect Dis. 2020 Feb; 22(1):e13216.View Related Profiles.

Moss, Alan
Branch-Elliman, Westyn

PMID: 31769569

Moss AC. Editorial: Advances in gastrointestinal immunology. Curr Opin Gastroenterol. 2019 11; 35(6):485. PMID: 31567429; DOI: 10.1097/MOG.0000000000000586;

Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis. 2019 Oct 28; 13(11):1365-1371. PMID: 30911757; DOI: 10.1093/ecco-jcc/jjz067;

Gubatan J, Chou ND, Nielsen OH, Moss AC. Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 12; 50(11-12):1146-1158. PMID: 31647134; DOI: 10.1111/apt.15506;

Estill M, Hauser R, Nassan FL, Moss A, Krawetz SA. The effects of di-butyl phthalate exposure from medications on human sperm RNA among men. Sci Rep. 2019 08 27; 9(1):12397. PMID: 31455814; PMCID: PMC6711971; DOI: 10.1038/s41598-019-48441-5;

Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019 07; 94(7):1357-1373.View Related Profiles.

Moss, Alan
Farraye, Francis

PMID: 31272578

Moss AC. Putting TDM knowledge into practice. Frontline Gastroenterol. 2019 Oct; 10(4):327. PMID: 31682644; PMCID: PMC6788134; DOI: 10.1136/flgastro-2018-101159;

Huang J, Kelly CP, Bakirtzi K, Villafuerte Gálvez JA, Lyras D, Mileto SJ, Larcombe S, Xu H, Yang X, Shields KS, Zhu W, Zhang Y, Goldsmith JD, Patel IJ, Hansen J, Huang M, Yla-Herttuala S, Moss AC, Paredes-Sabja D, Pothoulakis C, Shah YM, Wang J, Chen X. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis. Nat Microbiol. 2019 02; 4(2):269-279. PMID: 30510170; PMCID: PMC6559218; DOI: 10.1038/s41564-018-0300-x;

Nassan FL, Korevaar TIM, Coull BA, Skakkebæk NE, Krawetz SA, Estill M, Hait EJ, Korzenik JR, Ford JB, De Poortere RA, Broeren MA, Moss AC, Zoeller TR, Hauser R. Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men. Int J Hyg Environ Health. 2019 01; 222(1):101-110. PMID: 30170956; PMCID: PMC6221978; DOI: 10.1016/j.ijheh.2018.08.008;

Xie A, Robles RJ, Mukherjee S, Zhang H, Feldbrügge L, Csizmadia E, Wu Y, Enjyoji K, Moss AC, Otterbein LE, Quintana FJ, Robson SC, Longhi MS. HIF-1a-induced xenobiotic transporters promote Th17 responses in Crohn's disease. J Autoimmun. 2018 11; 94:122-133. PMID: 30098863; PMCID: PMC6193817; DOI: 10.1016/j.jaut.2018.07.022;

Lin SC, Alonso CD, Moss AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. Transpl Infect Dis. 2018 Dec; 20(6):e12967. PMID: 30011107; DOI: 10.1111/tid.12967;

Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018 07; 34(4):217-225. PMID: 29762159; DOI: 10.1097/MOG.0000000000000449;

Nielsen OH, Rejnmark L, Moss AC. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. J Crohns Colitis. 2018 May 25; 12(6):742-752. PMID: 29529167; DOI: 10.1093/ecco-jcc/jjy025;

Ballou S, Hirsch W, Singh P, Rangan V, Nee J, Iturrino J, Sommers T, Zubiago J, Sengupta N, Bollom A, Jones M, Moss AC, Flier SN, Cheifetz AS, Lembo A. Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther. 2018 Apr; 47(7):913-921. PMID: 29411411; PMCID: PMC5927595; DOI: 10.1111/apt.14551;

O'Toole A, de Silva PS, Marc LG, Ulysse CA, Testa MA, Ting A, Moss A, Korzenik J, Friedman S. Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale. Inflamm Bowel Dis. 2018 01 18; 24(2):310-316. PMID: 29361102; PMCID: PMC6014620; DOI: 10.1093/ibd/izx053;

Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, Moss AC. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine. 2018 03; 103:38-45. PMID: 29324259; PMCID: PMC5808893; DOI: 10.1016/j.cyto.2017.12.023;

Gonzalez-Suarez B, Sengupta S, Moss AC. Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. World J Gastroenterol. 2017 Dec 07; 23(45):8082-8089. PMID: 29259384; PMCID: PMC5725303; DOI: 10.3748/wjg.v23.i45.8082;

Juncadella AC, Moss A. Fecal microbiota transplantation as a possible treatment of irritable bowel syndrome. Ann Transl Med. 2017 Dec; 5(24):506. PMID: 29299467; PMCID: PMC5750267; DOI: 10.21037/atm.2017.09.13;

Boyle MP, Moss AC, O'Toole AM, Vaughn B, Cheifetz AS. C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. J Dig Dis. 2017 Dec; 18(12):678-683. PMID: 29119722; DOI: 10.1111/1751-2980.12560;

Nguyen VQ, Mays JL, Lang M, Wu Y, Dassopoulos T, Regueiro M, Moss A, Proctor DD, Sorrentino D. Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey. Dig Dis Sci. 2018 01; 63(1):53-60. PMID: 29147878; DOI: 10.1007/s10620-017-4844-z;

Nassan FL, Coull BA, Skakkebaek NE, Andersson AM, Williams MA, Mínguez-Alarcón L, Krawetz SA, Hall JE, Hait EJ, Korzenik JR, Ford JB, Moss AC, Hauser R. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men. Environ Res. 2018 01; 160:121-131. PMID: 28978458; PMCID: PMC5705343; DOI: 10.1016/j.envres.2017.09.025;

Feldbrügge L, Moss AC, Yee EU, Csizmadia E, Mitsuhashi S, Longhi MS, Sandhu B, Stephan H, Wu Y, Cheifetz AS, Müller CE, Sévigny J, Robson SC, Jiang ZG. Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis. 2017 Sep 01; 11(9):1113-1123. PMID: 28472257; PMCID: PMC5881706; DOI: 10.1093/ecco-jcc/jjx058;

Flores BM, O'Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Dec; 86(6):1006-1011.e8. PMID: 28750838; DOI: 10.1016/j.gie.2017.07.028;

Longhi MS, Moss A, Jiang ZG, Robson SC. Purinergic signaling during intestinal inflammation. J Mol Med (Berl). 2017 Sep; 95(9):915-925. PMID: 28547076; PMCID: PMC5702590; DOI: 10.1007/s00109-017-1545-1;

Longhi MS, Vuerich M, Kalbasi A, Kenison JE, Yeste A, Csizmadia E, Vaughn B, Feldbrugge L, Mitsuhashi S, Wegiel B, Otterbein L, Moss A, Quintana FJ, Robson SC. Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight. 2017 May 04; 2(9).View Related Profiles.

Moss, Alan
Kenison, Jessica

PMID: 28469075; PMCID: PMC5414551; DOI: 10.1172/jci.insight.92791;

Gubatan JMB, Moss AC. Reply. Clin Gastroenterol Hepatol. 2017 07; 15(7):1136-1137. PMID: 28377073; DOI: 10.1016/j.cgh.2017.03.037;

Gianotti RJ, Moss AC. Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Apr; 13(4):209-213. PMID: 28546791; PMCID: PMC5441021

Cury DB, de Souza AW, Vianna GA, Odashiro D, Farias A, Moss AC. Cutaneous Vasculitis in a Patient with Crohn's Disease Treated with Adalimumab. Inflamm Bowel Dis. 2017 01; 23(1):E1-E2. PMID: 27893546; DOI: 10.1097/MIB.0000000000000982;

Gianotti RJ, Moss AC. The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 11; 22(11):2704-2710. PMID: 27755271; DOI: 10.1097/MIB.0000000000000950;

Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 2016 09; 22(9):2182-90. PMID: 27542133; PMCID: PMC4995064; DOI: 10.1097/MIB.0000000000000893;

Nassan FL, Coull BA, Skakkebaek NE, Williams MA, Dadd R, Mínguez-Alarcón L, Krawetz SA, Hait EJ, Korzenik JR, Moss AC, Ford JB, Hauser R. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. Environ Int. 2016 Oct; 95:120-30. PMID: 27575365; PMCID: PMC5027995; DOI: 10.1016/j.envint.2016.08.006;

Patil DT, Moss AC, Odze RD. Role of Histologic Inflammation in the Natural History of Ulcerative Colitis. Gastrointest Endosc Clin N Am. 2016 Oct; 26(4):629-40. PMID: 27633592; DOI: 10.1016/j.giec.2016.06.009;

Mitsuhashi S, Feldbrügge L, Csizmadia E, Mitsuhashi M, Robson SC, Moss AC. Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflamm Bowel Dis. 2016 07; 22(7):1587-95. PMID: 27271497; PMCID: PMC4911338; DOI: 10.1097/MIB.0000000000000840;

Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2017 02; 15(2):240-246.e1. PMID: 27266980; PMCID: PMC5136522; DOI: 10.1016/j.cgh.2016.05.035;

Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. Am J Gastroenterol. 2016 05; 111(5):685-90. PMID: 26977756; DOI: 10.1038/ajg.2016.50;

Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. J Crohns Colitis. 2016 May; 10(5):619-25. PMID: 26763722; PMCID: PMC4957454; DOI: 10.1093/ecco-jcc/jjw007;

Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015 Dec; 21(12):2873-8. PMID: 26313693; DOI: 10.1097/MIB.0000000000000562;

Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, Martin ST, Rispens T, Cullen G, Mulcahy HE, Cheifetz AS, Moss AC, Robson SC, Doherty GA, Ryan EJ. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Dec; 21(12):2806-14. PMID: 26332314; DOI: 10.1097/MIB.0000000000000566;

Bai A, Moss A, Rothweiler S, Serena Longhi M, Wu Y, Junger WG, Robson SC. NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2015 Nov 09; 6:8819. PMID: 26549640; PMCID: PMC4667632; DOI: 10.1038/ncomms9819;

O'Connor A, Packey CD, Akbari M, Moss AC. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov; 21(11):2562-9. PMID: 26296062; DOI: 10.1097/MIB.0000000000000540;

Sahi KS, Lee KS, Moss A, Yee E, Allard F, Brook A, Mortele KJ. MR Enterography of the Ileoanal Pouch: Descriptive Radiologic Analysis With Endoscopic and Pathologic Correlation. AJR Am J Roentgenol. 2015 Nov; 205(5):W478-84. PMID: 26496569; DOI: 10.2214/AJR.14.14212;

Moss A, Pham NV. Guidelines for screening and surveillance in inflammatory bowel disease: Just a "rough guideline" or a cornerstone of high-quality modern medical practice? Gastrointest Endosc. 2015 Oct; 82(4):715-7. PMID: 26385279; DOI: 10.1016/j.gie.2015.05.042;

Abhyankar A, Moss AC. Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Aug; 21(8):1976-81. PMID: 25844962; PMCID: PMC4509976; DOI: 10.1097/MIB.0000000000000386;

O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep. 2015 Aug; 17(8):32. PMID: 26188882; DOI: 10.1007/s11894-015-0453-1;

Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015 Feb; 3(1):63-8. PMID: 25567472; PMCID: PMC4324872; DOI: 10.1093/gastro/gou087;

Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2014; (12):CD005046. PMID: 25485740; DOI: 10.1002/14651858.CD005046.pub3;

Moss AC. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014 Nov; 40(10):1249. PMID: 25303382; DOI: 10.1111/apt.12966;

Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. PMID: 25192499; PMCID: PMC5557346; DOI: 10.1097/MIB.0000000000000156;

Franquet E, Palmer MR, Gifford AE, Selen DJ, Chen YC, Sedora-Roman N, Joyce RM, Kolodny GM, Moss AC. Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. Nucl Med Commun. 2014 Oct; 35(10):1026-31. PMID: 25076161; DOI: 10.1097/MNM.0000000000000170;

Bai A, Moss A, Kokkotou E, Usheva A, Sun X, Cheifetz A, Zheng Y, Longhi MS, Gao W, Wu Y, Robson SC. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol. 2014 Oct 01; 193(7):3366-77. PMID: 25172498; PMCID: PMC4170017; DOI: 10.4049/jimmunol.1400346;

Jiang ZG, Wu Y, Csizmadia E, Feldbrügge L, Enjyoji K, Tigges J, Toxavidis V, Stephan H, Müller CE, Müller CE, McKnight CJ, Moss A, Robson SC. Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma. Purinergic Signal. 2014 Dec; 10(4):611-8.View Related Profiles.

Moss, Alan
McKnight, C.

PMID: 25165006; PMCID: PMC4272360; DOI: 10.1007/s11302-014-9423-6;

Cury DB, Moss AC. Treatment of Crohn's disease in pregnant women: drug and multidisciplinary approaches. World J Gastroenterol. 2014 Jul 21; 20(27):8790-5. PMID: 25083053; PMCID: PMC4112876; DOI: 10.3748/wjg.v20.i27.8790;

Feuerstein JD, Shah S, Najarian R, Nagle D, Moss AC. A fatal case of diffuse enteritis after colectomy for ulcerative colitis: a case report and review of the literature. Am J Gastroenterol. 2014 Jul; 109(7):1086-9.View Related Profiles.

Moss, Alan
Feuerstein, Joseph

PMID: 24989103; DOI: 10.1038/ajg.2014.118;

Moss AC. The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease. Curr Opin Gastroenterol. 2014 Jul; 30(4):365-9. PMID: 24811053; DOI: 10.1097/MOG.0000000000000082;

Moss AC, Lillis Y, Edwards George JB, Choudhry NK, Berg AH, Cheifetz AS, Horowitz G, Leffler DA. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014 Dec; 109(12):1850-5. PMID: 24913040; DOI: 10.1038/ajg.2014.158;

Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014 May; 20(5):856-60. PMID: 24681654; PMCID: PMC4077052; DOI: 10.1097/MIB.0000000000000016;

Sura SP, Ahmed A, Cheifetz AS, Moss AC. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol. 2014 Apr; 48(4):351-5. PMID: 24492405; PMCID: PMC3956001; DOI: 10.1097/MCG.0000000000000083;

O'Connor A, Moss AC. Current and emerging maintenance therapies for ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2014 May; 8(4):359-68. PMID: 24650224; DOI: 10.1586/17474124.2014.896193;

Pleet JL, Vaughn BP, Morris JA, Moss AC, Cheifetz AS. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment Pharmacol Ther. 2014 May; 39(9):940-8. PMID: 24605866; PMCID: PMC5552167; DOI: 10.1111/apt.12691;

Moss AC. Residual inflammation and ulcerative colitis in remission. Gastroenterol Hepatol (N Y). 2014 Mar; 10(3):181-3. PMID: 24829545; PMCID: PMC4014050

Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm. 2014 Mar; 20(3):309-14. PMID: 24564811; DOI: 10.18553/jmcp.2014.20.3.309;

Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis. 2014 Mar; 20(3):545-52. PMID: 24407484; PMCID: PMC3932523; DOI: 10.1097/01.MIB.0000440983.86659.81;

Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol. 2014 Feb 07; 20(5):1147-54. PMID: 24574791; PMCID: PMC3921499; DOI: 10.3748/wjg.v20.i5.1147;

Longhi MS, Moss A, Bai A, Wu Y, Huang H, Cheifetz A, Quintana FJ, Robson SC. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One. 2014; 9(2):e87956. PMID: 24505337; PMCID: PMC3914873; DOI: 10.1371/journal.pone.0087956;

O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jan; 20(1):1-6. PMID: 24280879; DOI: 10.1097/01.MIB.0000436951.80898.6d;

Moss AC. Therapeutic drug monitoring, mucosal healing, deep remission: the path to nirvana in Crohn's disease? Clin Gastroenterol Hepatol. 2014 Mar; 12(3):432-3. PMID: 24370555; DOI: 10.1016/j.cgh.2013.12.022;

Safaie P, Ham M, Kuang P, Mehta AS, Wang M, Cheifetz AS, Robson S, Lau D, Block TM, Moss AC. Lectin-reactive anti-a-gal in patients with Crohn's disease: correlation with clinical phenotypes. Inflamm Bowel Dis. 2013 Dec; 19(13):2796-800. PMID: 24185312; PMCID: PMC4112456; DOI: 10.1097/01.MIB.0000435437.76741.cb;

Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond). 2013 Nov; 3(11):1057-1069. PMID: 24533177; PMCID: PMC3921900; DOI: 10.4155/cli.13.97;

Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013 Nov; 38(10):1188-97. PMID: 24118102; DOI: 10.1111/apt.12507;

Abhyankar A, Ham M, Moss AC. Commentary: impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease--authors' reply. Aliment Pharmacol Ther. 2013 Oct; 38(7):843. PMID: 24001099; DOI: 10.1111/apt.12457;

Cury DB, Moss AC, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis. 2013; 6:139-42. PMID: 23935383; PMCID: PMC3735273; DOI: 10.2147/IJNRD.S45466;

Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Sep; 38(5):460-6. PMID: 23855477; PMCID: PMC3749828; DOI: 10.1111/apt.12417;

Moss AC. True costs of infliximab testing and administration. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):346. PMID: 23811252; DOI: 10.1016/j.cgh.2013.06.007;

Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol. 2013 Mar; 282(1):66-70. PMID: 23685388; PMCID: PMC4080304; DOI: 10.1016/j.cellimm.2013.04.004;

Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013 Aug; 11(8):991-6. PMID: 23591275; PMCID: PMC3753658; DOI: 10.1016/j.cgh.2013.02.030;

Moss AC. Prevention of postoperative recurrence of Crohn's disease: what does the evidence support? Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):856-9. PMID: 23446339; DOI: 10.1097/MIB.0b013e3182802c21;

Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):779-84. PMID: 23446338; PMCID: PMC3749843; DOI: 10.1097/MIB.0b013e3182802b0e;

Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013 Apr; 37(8):786-94. PMID: 23432394; DOI: 10.1111/apt.12262;

Gifford A, Moss AC. Comment on Moshkovska et al. Inflamm Bowel Dis. 2013 Feb; 19(2):E19. PMID: 22179973

Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013 Feb; 108(2):249-55. PMID: 23295279

Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013 Jan; 108(1):40-7; quiz 48. PMID: 23147525; PMCID: PMC3561464; DOI: 10.1038/ajg.2012.363;

Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, Csizmadia E, Nowak M, Cheifetz AS, Moss AC, Robson SC. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol. 2012 Nov; 42(11):3062-72. PMID: 22965858; PMCID: PMC3556646; DOI: 10.1002/eji.201242623;

Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 Oct 17; 10:CD008424. PMID: 23076948; PMCID: PMC4001731; DOI: 10.1002/14651858.CD008424.pub2;

Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012; 4:41-50. PMID: 22888278; PMCID: PMC3413022; DOI: 10.2147/CPAA.S26556;

Wang K, Chen YC, Palmer MR, Tal I, Ahmed A, Moss AC, Kolodny GM. Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. Nucl Med Commun. 2012 Jun; 33(6):641-7. PMID: 22240934

Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012 Mar; 5(2):113-23. PMID: 22390554; PMCID: PMC3314328; DOI: 10.1586/ecp.12.2;

Doherty G, Moss AC. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery. Am J Gastroenterol. 2012 Mar; 107(3):487; author reply 487-8. PMID: 22388032

Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012 Jun; 18(6):1057-63. PMID: 21953829; DOI: 10.1002/ibd.21824;

Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2012 Sep; 18(9):1608-16.View Related Profiles.

Moss, Alan
Miksad, Rebecca

PMID: 21905173; PMCID: PMC3381977; DOI: 10.1002/ibd.21904;

Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis. 2012 Apr; 18(4):691-6. PMID: 21648022; DOI: 10.1002/ibd.21783;

Lahiff C, Moss AC. Cyclosporine in the management of severe ulcerative colitis while breast-feeding. Inflamm Bowel Dis. 2011 Jul; 17(7):E78. PMID: 21538721

Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc. 2011 Jul; 74(1):167-75. PMID: 21497806

Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis. 2011 Jul; 17(7):E66. PMID: 21484966

Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011 Dec; 17(12):2585-93. PMID: 21484967

Cheifetz AS, Stern J, Garud S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol. 2011 Feb; 45(2):107-12. PMID: 20679905; DOI: 10.1097/MCG.0b013e3181e883dd;

Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010 Sep; 16(9):1620-7. PMID: 20232408

Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". Am J Gastroenterol. 2010 Sep; 105(9):2111; author reply 2111-2. PMID: 20818355

Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Aug; 16(8):1393-6. PMID: 19998457; DOI: 10.1002/ibd.21180;

Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Rev Clin Immunol. 2010 Jul; 6(4):521-6. PMID: 20594123

Cury DB, Moss AC, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm Bowel Dis. 2010 May; 16(5):723-4. PMID: 19728388

Moss AC. CMV in moderately active colitis: much ado about nothing? Dig Dis Sci. 2010 Apr; 55(4):880-2. PMID: 20204696

Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther. 2010 Apr; 31(8):802-9. PMID: 20055785; DOI: 10.1111/j.1365-2036.2010.04231.x;

Lawlor G, Moss AC. Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol. 2009; 2:149-61. PMID: 21694839; PMCID: PMC3108644

Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, Cheifetz AS. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis. 2010 Jun; 4(2):171-5. PMID: 21122501; DOI: 10.1016/j.crohns.2009.10.002;

Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD006873. PMID: 19821389; DOI: 10.1002/14651858.CD006873.pub2;

Tukey M, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2734-9. PMID: 19584828; DOI: 10.1038/ajg.2009.404;

Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010 May; 55(5):1413-20. PMID: 19533357; DOI: 10.1007/s10620-009-0856-7;

Mehta BP, Shmerling RH, Moss AC. Pseudogout after polyethylene glycol bowel cleansing. J Clin Gastroenterol. 2009 Jan; 43(1):95-6. PMID: 18528291

Fernandez-Becker NQ, Moss AC. In silico analysis of T-bet activity in peripheral blood mononuclear cells in patients with inflammatory bowel disease (IBD). In Silico Biol. 2009; 9(5-6):355-63. PMID: 22430437; DOI: 10.3233/ISB-2009-0410;

Moss AC, Cheifetz AS. How often is a diagnosis of ulcerative colitis changed to Crohn's disease and vice versa? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S155-6. PMID: 18816774

Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O'Brien M, Maratos-Flier E, Pothoulakis C. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10613-8.View Related Profiles.

Moss, Alan
O'Brien, Michael

PMID: 18650383; PMCID: PMC2492477; DOI: 10.1073/pnas.0804536105;

Koon HW, Zhao D, Xu H, Bowe C, Moss A, Moyer MP, Pothoulakis C. Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. Am J Pathol. 2008 Aug; 173(2):400-10. PMID: 18599605; PMCID: PMC2475777; DOI: 10.2353/ajpath.2008.080222;

Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther. 2008 Jul; 28(2):221-7. PMID: 18485127; DOI: 10.1111/j.1365-2036.2008.03734.x;

Patil SA, Moss AC. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr; 2(2):177-84. PMID: 19072352

Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008 Mar; 52(3):1121-6.View Related Profiles.

Moss, Alan
O'Brien, Michael

PMID: 18195066; PMCID: PMC2258528; DOI: 10.1128/AAC.01143-07;

Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008; 68(9):1157-67. PMID: 18547130

Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008; 68(8):1089-103. PMID: 18484800

Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol. 2007 Dec; 19(12):1119-24. PMID: 17998839

Moss AC, Cheifetz AS. Reducing the torment of diarrhea: tormentil for active ulcerative colitis. J Clin Gastroenterol. 2007 Oct; 41(9):797-8. PMID: 17881923

Moss AC, Callery MP, Falchuk KR. Gastrointestinal [corrected] stromal tumor of the ampulla of vater mimicking a duodenal ulcer. Clin Gastroenterol Hepatol. 2007 Oct; 5(10):A26. PMID: 17916534

Murray D, Doran P, MacMathuna P, Moss AC. In silico gene expression analysis--an overview. Mol Cancer. 2007 Aug 07; 6:50. PMID: 17683638; PMCID: PMC1964762; DOI: 10.1186/1476-4598-6-50;

Moss AC, Farrell RJ. Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology. 2007 Jun; 132(7):2609-11. PMID: 17570236

Moss AC. Curcumin for maintenance therapy in ulcerative colitis. Clin Gastroenterol Hepatol. 2007 May; 5(5):642; author reply 642. PMID: 17478350

Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut. 2007 Sep; 56(9):1210-7. PMID: 17412781; PMCID: PMC1954994; DOI: 10.1136/gut.2006.110668;

Moss AC, Kelly CP. Reflux, dyspepsia, and disorders of the foregut. South Med J. 2007 Mar; 100(3):266-72; quiz 273, 294. PMID: 17396730

Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf. 2007 Mar; 6(2):99-107. PMID: 17367256

Moss AC, Doran PP, Macmathuna P. In Silico Promoter Analysis can Predict Genes of Functional Relevance in Cell Proliferation: Validation in a Colon Cancer Model. Transl Oncogenomics. 2007; 2:1-16. PMID: 23641142; PMCID: PMC3634709

Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007 Apr; 33(2):213-21. PMID: 17157990

Moss AC, Farrell RJ. Infliximab for induction and maintenance therapy for ulcerative colitis. Gastroenterology. 2006 Nov; 131(5):1649-51; discussion 1651. PMID: 17067595

Kokkotou E, Torres D, Moss AC, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol. 2006 Sep 1; 177(5):3355-61.View Related Profiles.

Moss, Alan
O'Brien, Michael

PMID: 16920976

Moss AC, Cheifetz AS, Peppercorn MA. Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006 May; 3(5):290-3. PMID: 16673009

Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):216-21. PMID: 16678123; DOI: 10.1016/j.bbrc.2006.04.094;

Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P. Net1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer. 2006 Apr 24; 94(8):1204-12. PMID: 16552434; PMCID: PMC2361249; DOI: 10.1038/sj.bjc.6603054;

Moss AC, Farrell RJ. Lymphoma risk with azathioprine/6-MP therapy-read beyond the headlines. Gastroenterology. 2006 Apr; 130(4):1363-4. PMID: 16618430

Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006 Jan 25; (1):CD004200. PMID: 16437477; DOI: 10.1002/14651858.CD004200.pub2;

Moss AC, Brennan AM, Cheifetz AS, Peppercorn MA. Thyroid cancer and Crohn's disease: association or coincidence? Inflamm Bowel Dis. 2006 Jan; 12(1):79-80. PMID: 16374265

Moss AC, Farrell RJ. Adding fuel to the fire: GM-CSF for active Crohn's disease. Gastroenterology. 2005 Dec; 129(6):2115-7. PMID: 16344081

Moss AC, Dugal T, Silke B. Attitudes to peer review as a competence assurance structure--results of a survey of Irish physicians. Ir J Med Sci. 2005 Jul-Sep; 174(3):43-6. PMID: 16285338; DOI: 10.1007/BF03169147;

Bruzzi JF, Moss AC, Brennan DD, MacMathuna P, Fenlon HM. Colonic surveillance by CT colonography using axial images only. Eur Radiol. 2004 May; 14(5):763-7. PMID: 14986051; DOI: 10.1007/s00330-004-2244-1;

Bruzzi JF, Moss AC, Brennan DD, MacMathuna P, Fenlon HM. Efficacy of IV Buscopan as a muscle relaxant in CT colonography. Eur Radiol. 2003 Oct; 13(10):2264-70. PMID: 12942279; DOI: 10.1007/s00330-003-2012-7;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 159 publications over 21 distinct years, with a maximum of 20 publications in 2014

Bar chart showing 159 publications over 21 distinct years, with a maximum of 20 publications in 2014

Year	Publications
2003	1
2004	1
2005	2
2006	9
2007	10
2008	8
2009	7
2010	7
2011	8
2012	7
2013	15
2014	20
2015	9
2016	8
2017	12
2018	9
2019	7
2020	11
2021	5
2022	2
2023	1

Tweets by moss_md

Twitter likes by moss_md

VIDEO: Point-of-care, drug-level assays help predict ‘best time, best dose’ in IBD therapy

Healio 1/30/2023

Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study

Medscape 7/11/2022

Biosimilars Face High Expectations, But Also Barriers to Acceptance

Gastroenterology Consultant 6/27/2020

2019 Crohn’s & Colitis Foundation: Litwinn Pioneer’s Award

2019 School of Medicine, Dublin University: Visiting Professor in IBD

2018 Harvard Medical Faculty Physicians: Physician Leadership Program

2017 UCLA Digestive Disease Division: Visiting Professor

2017 University Clinic Barcelona: Visiting Professor

2015 Colorectal Research Center, University College Dublin: ‘State of the Art Lecture’

2014 American College of Gastroenterology: ‘Best of DDW’ Poster Nominee

2013 American College of Gastroenterology: IBD Abstract Research Award

2012 Harvard Medical School: Mentoring Award Nominee

2012 State University of New York: Goldwitz-Allen Memorial Lectureship

2012 Beth Israel Deaconess Medical Center: Rabb Award for GI Research

2011 American Gastroenterology Association: Abstract of Distinction Award

2008-2010 The Academy at Harvard Medical School: Excellence in Tutoring Award

2008 American College of Gastroenterology: Presidential Abstract Award

2006 American Gastroenterology Association: Fellow’s Travel Award

2005 American Society for Clinical Oncology: Foundation Merit Award

2004 European Crohn’s & Colitis Organization: Trainee Travel Award

2002 United European Gastroenterology Federation: Outstanding Abstract Award, Research

2002 University College Dublin: Excellence in Clinical Teaching

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Ulcerative Colitis
Crohn's Disease
Inflammatory Bowel Disease
Microbiomes, Human

Dr Moss has mentored medical students, residents and GI fellows on clinical and translation projects. These have led to 1st author papers on high-impact peer-reviewed journals, in addition to abstracts and research experience.

Available to Mentor as: (Review Mentor Role Definitions):